Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on June 22, 2020. The company is an emerging growth company incorporated in Nevada, with its principal executive offices in La Jolla, California. Its common stock (ARTL) and warrants (ARTLW) trade on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a $25,000 fee payable to The Research Foundation for the State University of New York (the "Foundation") in connection with a license expansion.
Material Changes
On June 22, 2020, the Company executed a Project Invention Exercise Notice to the Foundation. This action indicates the Company's intent to obtain a commercial license for certain compounds (the "Project Invention") developed under a Sponsored Research Agreement dated July 10, 2018. Upon payment of the fee, the definition of Licensed Patents in the existing License Agreement with Stony Brook University (dated January 18, 2018) will be expanded to include the Project Invention.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond the operational context of the license exercise. The document focuses solely on the administrative execution of the license expansion.
Investor Verification Checklist
- Verify the status of the $25,000 fee payment to the Foundation.
- Confirm the specific compounds included in the "Project Invention" and their development stage.
- Review the original January 18, 2018 License Agreement with Stony Brook University to understand the baseline terms being expanded.
- Check subsequent filings for any financial impact of this license on the company's cash position.